State of New Mexico 12-17 ATOD Prevention Programs
______Project, Site ID#: ____
2013Strategies for Success Program Findings Sheet –Middle School
Project Goal and Objectives:
Program Setting:
Evaluation Design and Brief Sample Description:
Table 1 describes the sample broken down by biological sex.
Table 1: Demographics for middle school SFS program participants by biological sex
MALES / FEMALESN / % / N / %
Age
10 / 0 / 0.0 / 0 / 0.0
11 / 0 / 0.0 / 0 / 0.0
12 / 0 / 0.0 / 0 / 0.0
13 / 0 / 0.0 / 0 / 0.0
14 or over / 0 / 0.0 / 0 / 0.0
Grade
6th grade / 0 / 0.0 / 0 / 0.0
7th grade / 0 / 0.0 / 0 / 0.0
8th grade / 0 / 0.0 / 0 / 0.0
Race/Ethnicity
White / 0 / 0.0 / 0 / 0.0
Hispanic / 0 / 0.0 / 0 / 0.0
Native American / 0 / 0.0 / 0 / 0.0
Other / 0 / 0.0 / 0 / 0.0
Language Other than English Spoken Often at Home
No / 0 / 0.0 / 0 / 0.0
Yes / 0 / 0.0 / 0 / 0.0
Mean Age for Male SFS Program Participants:
μ= 00.0 sd= 0.0 range: Min = 00Max = 00
Mean Age for Female SFS Program Participants:
μ= 00.0sd= 0.0 range: Min = 00Max =00
Tables 2 captures the percentage of middle school SFS program participants self-reporting any past 30-day substance use at pre-test & post-test, by biological sex and the % change from pre-test to post-test
Table 2: Past 30-day ATOD useadifferences from pre-test to post-testfor middle school SFS program participants by biological sex
Male / FemaleSubstance / %
Pretest / %
Posttest / Change / %
Pretest / %
Posttest / Change
Cigarettes
(male pretestn= posttest n= )
(female pretest n= posttest n= ) / 0.0 / 0.0 / 0.0 / 0.0 / 0.0 / 0.0
Chewing tobacco
(male pretest n= posttest n= )
(female pretest n= posttest n= ) / 0.0 / 0.0 / 0.0 / 0.0 / 0.0 / 0.0
Alcohol
(male pretest n= posttest n= )
(female pretest n= posttest n= ) / 0.0 / 0.0 / 0.0 / 0.0 / 0.0 / 0.0
Binge drinking
(male pretest n= posttest n= )
(female pretest n= posttest n= ) / 0.0 / 0.0 / 0.0 / 0.0 / 0.0 / 0.0
Marijuana
(male pretest n= posttest n= )
(female pretest n= posttest n= ) / 0.0 / 0.0 / 0.0 / 0.0 / 0.0 / 0.0
Inhalant ever use
(male pretest n= posttest n= )
(female pretest n= posttest n= ) / 0.0 / 0.0 / 0.0 / 0.0 / 0.0 / 0.0
Any prescription medication not prescribed
(male pretest n= posttest n= )
(female pretest n= posttest n= ) / 0.0 / 0.0 / 0.0 / 0.0 / 0.0 / 0.0
Any prescription pain pills not prescribed
(male pretest n= posttest n= )
(female pretest n= posttest n= ) / 0.0 / 0.0 / 0.0 / 0.0 / 0.0 / 0.0
Any Ritalin, Adderal, or Prozac not prescribed
(male pretest n= posttest n= )
(female pretest n= posttest n= ) / 0.0 / 0.0 / 0.0 / 0.0 / 0.0 / 0.0
Any prescription sleep aids or tranquilizers not prescribed
(male pretest n= posttest n= )
(female pretest n= posttest n= ) / 0.0 / 0.0 / 0.0 / 0.0 / 0.0 / 0.0
Any other medicationsnot prescribed (male pretest n= posttest n= )
(female pretest n= posttest n= ) / 0.0 / 0.0 / 0.0 / 0.0 / 0.0 / 0.0
aDichotomous substance use variable (yes or no).
1
Table 3 capturesself reported ATOD use at baseline & post-test amongmiddle school SFS program participants who report any ATOD use at baseline and had no missing values at both baseline and posttest.
Table 3: Past 30-day ATOD useadifferences from pre-test to post-testamongmiddle school SFS program participants who report any ATOD use at baseline and had no missing values at both baseline and posttest.
Past 30 Day Substance Use / %Pre-test / %
Post-test / Change
Cigarettes (n= ) / 0.0 / 0.0 / 0.0
Chewing tobacco (n= ) / 0.0 / 0.0 / 0.0
Alcohol (n= ) / 0.0 / 0.0 / 0.0
Binge drinking (n= ) / 0.0 / 0.0 / 0.0
Marijuana (n= ) / 0.0 / 0.0 / 0.0
Any prescription medication not prescribed (n= ) / 0.0 / 0.0 / 0.0
Any prescription pain pills not prescribed (n= ) / 0.0 / 0.0 / 0.0
Any Ritalin, Adderal, or Prozac not prescribed (n= ) / 0.0 / 0.0 / 0.0
Any prescription sleep aids or tranquilizers not prescribed (n= ) / 0.0 / 0.0 / 0.0
Any other medications not prescribed (n= ) / 0.0 / 0.0 / 0.0
aDichotomous substance use variable (yes or no).
1
Table 4 captures the percentage of respondentswho reported any ATOD use at pre-test among the corresponding ordinal ATOD measures.
Table 4: The percentage of past 30 day ATOD use reported among middle school SFS program participants
Cigarettes / 0 days / 1-2 days / 3-5 days / 6-9 days / 10-19 days / 20-29 days / All 30 daysPre-test (%) / 0.0 / 0.0 / 0.0 / 0.0 / 0.0 / 0.0
Post-test (%) / 0.0 / 0.0 / 0.0 / 0.0 / 0.0 / 0.0 / 0.0
Chewing tobacco / 0 days / 1-2 days / 3-5 days / 6-9 days / 10-19 days / 20-29 days / All 30 days
Pre-test (%) / 0.0 / 0.0 / 0.0 / 0.0 / 0.0 / 0.0
Post-test (%) / 0.0 / 0.0 / 0.0 / 0.0 / 0.0 / 0.0 / 0.0
Alcohol / 0 days / 1-2 days / 3-5 days / 6-9 days / 10-19 days / 20-29 days / All 30 days
Pre-test (%) / 0.0 / 0.0 / 0.0 / 0.0 / 0.0 / 0.0
Post-test (%) / 0.0 / 0.0 / 0.0 / 0.0 / 0.0 / 0.0 / 0.0
Binge drinking / 0 days / 1 day / 2 days / 3-5 days / 6-9 days / 10-19 days / 20 or more days
Pre-test (%) / 0.0 / 0.0 / 0.0 / 0.0 / 0.0 / 0.0
Post-test (%) / 0.0 / 0.0 / 0.0 / 0.0 / 0.0 / 0.0 / 0.0
Marijuana / 0 times / 1-2 times / 3-9 times / 10-19 times / 20-39 times / 40 or more times
Pre-test (%) / 0.0 / 0.0 / 0.0 / 0.0 / 0.0
Post-test (%) / 0.0 / 0.0 / 0.0 / 0.0 / 0.0 / 0.0
Table 5 provides results from the GLM analyses that examine the effect of time on the post-test estimates controlling for the effect of baseline estimates on post-test estimates. Dichotomous ATOD use measures are used.
Table 5: Examining the effect of time on ATOD use at post-test controlling for baseline use.
Substance† / Base-line Mean / Post-Test Mean / F-test & sig.(indicated by asterisk[s]) / effect sizea / Desired Outcome
Cigarettes / 0.0 / 0.0 / 0.000 / .000 /
Chewing Tobacco / 0.0 / 0.0 / 0.000 / .000 /
Alcohol / 0.0 / 0.0 / 0.000 / .000 /
Binge Drinking / 0.0 / 0.0 / 0.000 / .000 /
Marijuana / 0.0 / 0.0 / 0.000 / .000 /
Any Prescription Medication Not Prescribed§ / 0.0 / 0.0 / 0.000 / .000 /
†Dichotomous (yes/no) ATOD use measures used
§Based on the combined responses to questions 26-30
a partial eta squared where effects are: small = .01, medium = .06, large = .14 or larger
*p .05, **p .01, ***p .001
Table 6a provides results from the GLM analyses that examine the effect of time on the posttest estimates of perceived risk of harm associated with ATOD use, attitudes towards ATOD use, and intentions to smoke controlling for the effect of baseline estimates on posttest estimates. Table 6b shows Cronbach’s alpha for risk of harm scale at pre- and posttest.
Table 6a: Examining the effect of time on ATOD use at post-test controlling for baseline use.
Risk and Protective Factors / Range / Baseline Mean Score / Post-Test Mean Score / F-test & sig.(indicated by asterisk[s]) / effect sizea / Desired Outcome
Min
Max
Risk of Harm Scale
(n= ) / 0-3 / 0.00 / 0.00 / 00.000 / .000 /
Parent Attitudes Toward ATOD use (n= ) / 0-3 / 0.00 / 0.00 / 00.000 / .000 /
Youth Attitudes Toward ATOD Use (n= ) / 0-3 / 0.00 / 0.00 / 00.000 / .000 /
Intentions to Smoke (limit to respondents who were not smoker at baseline)
Do you think you will try smoking a cigarette soon?
(n= ) / 0-1 / 0.00 / 0.00 / 00.000 / .000 /
Do you think you will smoke a cigarette at any time during the next year? (n= ) / 0-3 / 0.00 / 0.00 / 00.000 / .000 /
If one of your best friends offered you a cigarette, would you smoke it?
(n= ) / 0-3 / 0.00 / 0.00 / 00.000 / .000 /
Table 6b: Cronbach's Alpha at pre- and posttest
Cronbach's AlphaScale / Pretest / Posttest
Risk of Harm / .000 / .000
1
Discussion of Findings for Module A
Consider the following statements & questions as prompts only. You may remove these and summarize the information & findings you feel are most important to communicate to OSAP. This is also a space where you can include any graphs from the GLM analyses that you feel present a better picture of your results.
1) Note any observed trends in demographics that might affect your results. (e.g., predominantly female, predominantly Native American, etc.) (Table 1)
2)How did Past 30-day ATOD Use at Pre-test compare to Past 30-day ATOD use at Post-test for each substance? Note whether it increased, decreased, or stayed the same. Do you feel these are meaningful changes, regardless of significance. How did estimates differ when only those who reported use at baseline were included? Which do you think more accurately reflects the program effectiveness (if you have an opinion)? (Tables 2 & 3)
3)Describe the Percentage of ATOD Use at pre-test and post-test and note whether percentage increased, decreased, or stayed the same for each substance. How do the changes reflect on the effectiveness of the prevention programming (if they do at all)? (Table 4)
4)Provide a summary of the key results from the 2013 GLM Analysis on measures. Refer to the Guidance as necessary. (Tables 5 & 6)
5)What implications can be drawn about the prevention program(s) conducted based on these results. Are there areas where the program was very successful? Are there areas that need more attention next year?
6)Are there additional results & issues that are not represented in the tables that should be mentioned and brought to the attention of OSAP?
1